Pulmonary Embolism – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Pulmonary Embolism – Pipeline Review, H2 2020’, provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism

– The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects

– The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acticor Biotech SAS

China Resources Emde Biological Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Indiana Lysis Technologies LLC

Les Laboratoires Servier SAS

Tasly Pharmaceutical Group Co Ltd

Tianjin Pharmaceuticals Group Co Ltd

Valeo Pharma Inc

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pulmonary Embolism - Overview

Pulmonary Embolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pulmonary Embolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Embolism - Companies Involved in Therapeutics Development

Acticor Biotech SAS

China Resources Emde Biological Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Indiana Lysis Technologies LLC

Les Laboratoires Servier SAS

Tasly Pharmaceutical Group Co Ltd

Tianjin Pharmaceuticals Group Co Ltd

Valeo Pharma Inc

Verseon Corp

Pulmonary Embolism - Drug Profiles

ACT-017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Pulmonary Embolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Redesca - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pulmonary Embolism - Dormant Projects

Pulmonary Embolism - Discontinued Products

Pulmonary Embolism - Product Development Milestones

Featured News & Press Releases

Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Canada

Oct 25, 2017: IU-based drug-discovery startup aims to use nanotechnology to digest blood clots in lungs

Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition

Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Nov 09, 2016: Once-Daily Anticoagulant LIXIANA (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism

Oct 13, 2016: Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA (edoxaban)

Sep 01, 2016: Lixiana applies to National Health Insurance

Aug 26, 2015: UK’s NICE recommends once-daily LIXIANA (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults

Aug 07, 2015: NICE Recommends Once-daily Lixiana (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation

Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE

Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation

Dec 09, 2013: Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer

Sep 01, 2013: Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence

Oct 25, 2012: Daiichi Sankyo Completes Enrolment In Hokusai-VTE Phase III Study Of Edoxaban For Treatment And Prevention Of Recurrence Of VTE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pulmonary Embolism, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pulmonary Embolism – Pipeline by Acticor Biotech SAS, H2 2020

Pulmonary Embolism – Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, H2 2020

Pulmonary Embolism – Pipeline by Daiichi Sankyo Co Ltd, H2 2020

Pulmonary Embolism – Pipeline by F. Hoffmann-La Roche Ltd, H2 2020

Pulmonary Embolism – Pipeline by Indiana Lysis Technologies LLC, H2 2020

Pulmonary Embolism – Pipeline by Les Laboratoires Servier SAS, H2 2020

Pulmonary Embolism – Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020

Pulmonary Embolism – Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2020

Pulmonary Embolism – Pipeline by Valeo Pharma Inc, H2 2020

Pulmonary Embolism – Pipeline by Verseon Corp, H2 2020

Pulmonary Embolism – Dormant Projects, H2 2020

Pulmonary Embolism – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Pulmonary Embolism, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports